drugset / Trial / NCT01367236
Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare two different combination anti-HIV therapies over 48 weeks and to assess if differences in improvement in the function of the brain are observed over this period. The study will compare anti-HIV therapy combinations which are currently in use. The patients will not have had any previous treatment for their HIV infection.
Timeline
- Start
- 2013-01
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abacavir | Other / unclassified | 600 mg | — |
| Subject | Atazanavir | Other / unclassified | 300 mg | — |
| Subject | Darunavir | Small molecule | 800 mg | — |
| Subject | Lamivudine | Other / unclassified | 300 mg | — |
| Subject | Maraviroc | Other / unclassified | 150 mg | — |
| Subject | Tenofovir | Small molecule | 245 mg | — |
| Subject | emtricitabine | Other / unclassified | 200 mg | — |
| Background | Ritonavir | Other / unclassified | 100 mg | — |